Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Prosonix Elects Dr Ken Cunningham as Non-executive Chairman

Published: Wednesday, December 05, 2012
Last Updated: Wednesday, December 05, 2012
Bookmark and Share
Dr Cunningham replaces Dr Jim Philips, who is retiring from the Board of Directors.

Prosonix has announced the election of Dr Ken Cunningham as Non-executive Chairman. He replaces Dr Jim Philips, who has been Chairman of the Company since 2007, and is retiring from the Board of Directors.

Dr Cunningham was elected to the Board of Prosonix as a Non-executive Director in September 2011, and is also Chair of Prosonix’s Scientific Advisory Board.

He has over 20 years' experience in the pharmaceutical industry with a strong focus in recent years on respiratory drug development and drug delivery.

He is Chairman of PolyTherics Ltd and until August 2010 was CEO of Skyepharma plc. Before that he was Chief Executive Officer of Arakis Ltd, Vice-President European Affairs at Alza Corporation and Vice-President Clinical Development at Sequus Inc.

He holds a medical degree from St Mary's, Imperial College, London University.

Dr Ken Cunningham, said: “Over recent years, Prosonix’s particle engineering technology has repeatedly demonstrated its exciting potential for optimizing many of the respiratory medicines currently used in the treatment of asthma and COPD. During this period, the Company has made a successful transition from applying its technology to third party compounds to using it to build its own pipeline of directly substitutable generic and proprietary inhaled drugs based on improved versions of known drugs in simple, cost effective and already approved devices. I would like to take this opportunity, on behalf of the Prosonix Board, to thank Dr Phillips for his important contribution as Chairman during this period of transformation. I am very pleased to continue his work and help Prosonix deliver its corporate and clinical strategy, which is focused on building further value from the Company’s portfolio of inhaled drug candidates.”

Dr Jim Phillips, said: “After five years chairing Prosonix and helping shape it into the inhalation product-focused company it is today, I am delighted to hand over Chairmanship to Dr Ken Cunningham to bring his respiratory experience to bear towards the Company's future success.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Prosonix Enters Collaboration with Imperial College London
Collaborative research agreement to accelerate development of engineered combination respiratory medicines.
Thursday, July 05, 2012
Prosonix to Present at RDD 2012 and ATS 2012 International Conference
Prosonix will present a poster entitled ‘Engineered Combination Respiratory Medicines for Localized Drug Delivery’ at RDD.
Wednesday, May 09, 2012
Scientific News
Early Genetic Changes in Premalignant Colorectal Tissue Identified
Findings point to drivers of early cancer development, targets for cancer prevention therapies.
Scientists Find Evidence That Cancer Can Arise Changes
Researchers at Rockefeller University have found a mutation that affects the proteins that package DNA without changing the DNA itself can cause a rare form of cancer.
Breakthrough Approach to Breast Cancer Treatment
Scripps scientists have designed a drug candidate that decreases growth of breast cancer cells.
A Guide to CRISPR Gene Activation
A comparison of synthetic gene-activating Cas9 proteins can help guide research and development of therapeutic approaches.
Testing Non-Breast/Ovarian Cancer Genes
Researchers have found that expanding gene panel beyond breast/ovarian cancer genes in these patients does not add any clinical benefit. Instead, testing has produced more questions than answers.
Myeloid-Derived Suppressor Cells Play Role in Tumor Growth
Researchers at Baylor College of Medicine have reported a new mechanism that helps cancer cells engage myeloid-derived suppressor cells.
Cancer Cells Coordinate to Form Roving Clusters
Rice University scientists identify ‘smoking gun’ in metastasis of hybrid cells.
Poliovirus Therapy Wins 'Breakthrough' Status
FDA decision will fast-track research on breakthrough Duke brain cancer therapy.
Novel Way to Prevent Deadly Bacterial Infections
Monash scientists may have found a way to stop deadly bacteria from infecting patients. The discovery could lead to a whole new way of treating antibiotic-resistant “superbugs”
New Treatment for Pancreatic Cancer
Researchers at Purdue University have shown how controlling cholesterol metabolism in pancreatic cancer cells reduces metastasis.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!